Gianmarco Meier
Overview
Explore the profile of Gianmarco Meier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
103
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meier G, Thavarasah S, Ehrenbolger K, Hutter C, Hurlimann L, Barandun J, et al.
Nat Chem Biol
. 2022 Nov;
19(4):440-450.
PMID: 36443574
Drug efflux is a common resistance mechanism found in bacteria and cancer cells, but studies providing comprehensive functional insights are scarce. In this study, we performed deep mutational scanning (DMS)...
2.
Galazzo L, Meier G, Januliene D, Parey K, De Vecchis D, Striednig B, et al.
Sci Adv
. 2022 Oct;
8(41):eabn6845.
PMID: 36223470
Membrane proteins are currently investigated after detergent extraction from native cellular membranes and reconstitution into artificial liposomes or nanodiscs, thereby removing them from their physiological environment. However, to truly understand...
3.
Walter J, Scherer M, Hutter C, Garaeva A, Zimmermann I, Wyss M, et al.
EMBO Rep
. 2022 Mar;
23(4):e54199.
PMID: 35253970
The ongoing COVID-19 pandemic represents an unprecedented global health crisis. Here, we report the identification of a synthetic nanobody (sybody) pair, Sb#15 and Sb#68, that can bind simultaneously to the...
4.
Bordignon E, Seeger M, Galazzo L, Meier G
FEBS Lett
. 2020 Nov;
594(23):3839-3856.
PMID: 33219535
ATP-binding cassette (ABC) exporters have been studied now for more than four decades, and recent structural investigation has produced a large number of protein database entries. Yet, important questions about...
5.
Alijaj N, Moutel S, Gouveia Z, Gray M, Roveri M, Dzhumashev D, et al.
Cancers (Basel)
. 2020 Nov;
12(11).
PMID: 33182650
The fibroblast growth factor receptor 4 (FGFR4) is overexpressed in rhabdomyosarcoma (RMS) and represents a promising target for treatments based on specific and efficient antibodies. Despite progress, there is an...
6.
Galazzo L, Meier G, Timachi M, Hutter C, Seeger M, Bordignon E
Proc Natl Acad Sci U S A
. 2020 Jan;
117(5):2441-2448.
PMID: 31964841
Nanobodies are emerging tools in a variety of fields such as structural biology, cell imaging, and drug discovery. Here we pioneer the use of their spin-labeled variants as reporters of...
7.
The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells
Jaaks P, Meier G, Alijaj N, Brack E, Bode P, Koscielniak E, et al.
Oncotarget
. 2016 Aug;
7(47):76743-76755.
PMID: 27572312
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Success of current therapies is still limited and outcome is particularly poor for metastatic alveolar rhabdomyosarcoma (aRMS). We previously...